Status:
NOT_YET_RECRUITING
Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma
Lead Sponsor:
Odense University Hospital
Conditions:
Multiple Myeloma in Relapse
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The main goal in this open label, phase four, prospective, non-randomized, sponsor-initiated multicenter feasibility study is to evaluate the feasibility and safety of self-administration of subcutane...
Detailed Description
Introduction Subcutaneous (SC) daratumumab has significantly improved outcomes for patients with multiple myeloma (MM), allowing for longer survival with continuous treatment. However, this has also i...
Eligibility Criteria
Inclusion
- Diagnosed with MM
- Initiating treatment with SC daratumumab
- Able to read and understand the Danish language
- Are considered suitable for self-administration of SC daratumumab at home (in the opinion of the healthcare professional)
- Willing and able to complete questionnaires and participate in an interview
Exclusion
- Resident on an unbridged island
- Receiving co-treatment with other anti-myeloma treatments necessitating hospitals visits on days of home administration
- Anything related to their ability to self-administer SC daratumumab at home e.g. physical inabilities or cognitive impairment
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07191379
Start Date
January 1 2026
End Date
June 1 2027
Last Update
September 24 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.